Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of QLH11811 in Advanced or Metastatic NSCLC Patients Who Have Progressed After EGFR-TKI Treatment
Latest Information Update: 03 Apr 2023
At a glance
- Drugs QLH-11811 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 26 Mar 2023 The protocol was amended to addition of Sequential Interventional Study Model into the study.
- 26 Mar 2023 Status changed from not yet recruiting to recruiting.
- 30 Sep 2022 New trial record